PhD-Student
Andreas Dammann Andersen
Department of Neurology, Hospital of Southern Jutland
Projekt styring | ||
Projekt status | Closed | |
Data indsamlingsdatoer | ||
Start | 01.09.2014 | |
Slut | 15.09.2017 | |
This project focuses on biomarkers for Parkinson's disease, both in the cerebrospinal fluid as well as in blood. Biomarkers related to diagnosing Parkinson's disease as well as the severity of the disease will be sought out. Through a follow up study, possible prognostic biomarkers related to both disease severity and the risk of developing side effects to L-DOPA-treatment as involuntary movements called dyskinesias.
Parkinson's disease (PD) is the second most common neurodegenerative disease, with a prevalence of 1% in the population older than 60 years. When the degeneration of dopaminergic neurons in the substantia nigra reaches 50-60%, the lack of dopaminergic input to the striatum causes the characteristic motor symptoms including hypokinesia, postural instability, rigidity and resting tremor. The diagnosis is overwhealmingly based on these clinical symptoms.
There is no established disease modifying treatment and the continuous progression of the disease results in increasing disability. After 2-5 years of dopamine substituting treatment with L-DOPA, the treatment gradually loses its efficiency. Patients will invariably develop significant daily fluctuations of symptom severity, as well as potentially disabling involuntary movements, L-DOPA-induced dyskinesia (LID). The urgent need for earlier diagnostics, a better understanding of PD pathogenesis and assessment of disease progression as also evaluation of potential disease modifying drugs has resulted in extensive research in biomarkers.
This study focuses especially on LID, a field in which there are not many biomarker studies. Performing rating scales related to dyskinesia, possible links to certain biomarkers might be found, both related to current LID as well as the risk of developing LID.
Using internationally verified rating scales for each PD patient, established and new possible biomarkers related to disease severity will be studied, and through a one year follow up period, possible prognostic biomarkers might be identified.
By including neurological controls this study also focuses on biomarkers specifically related to diagnosing PD.
100 PD patients with varying disease severity and disease duration will be included in the study, recuited from the neurological departments in Sønderborg, Vejle, Odense and Roskilde as well as from a private neurological practice in Esbjerg.
50 of the included patients will be suffering from LID at baseline.
The approximately 30 age matched control patients included are undergoing lumbar puncture as part of a neurological investigation, recruited from the neurological department in Sønderborg.
Relevant clinical and demographic data from patient files will be included, including use of medicine, potential brain scans etc.
Two rating scales related to Parkinson's disease will be included (UPDRS, UDysRS) including a quiestionnaire and a clinical rating. Also included is two cognitive rating scales (MOCA and MMSE).
For both PD patients and controls spinal fluid samples as well as plasma and erythrocyte samples are collected.
Department of Neurology, Hospital of Southern Jutland
Center of Research in the Institute of Regional Health Research, University of Southern Denmark
Institute for Molecular Medicine, Neurobiology Research, University of Southern Denmark
University of Southern Denmark
Department of Neurology, Hospital Littlebelt
Department of Neurology, Roskilde Hospital
Department of Neurology, Odense University Hospital
Institute for Molecular Medicine, Neurobiology Research, University of Southern Denmark